Ask about this productRelated genes to: gp130 antibody
- Gene:
- ENPP3 NIH gene
- Name:
- ectonucleotide pyrophosphatase/phosphodiesterase 3
- Previous symbol:
- PDNP3
- Synonyms:
- PD-IBETA, gp130RB13-6, B10, CD203c
- Chromosome:
- 6q23.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-10
- Date modifiied:
- 2016-10-05
Related products to: gp130 antibody
Related articles to: gp130 antibody
- In this study, new imidazo[1,2-a]pyrazine derivative 15 (YS3074) and pyrazine derivative 17 (YS3375) are identified and optimized as potent and selective ENPP1 inhibitors. Compounds 15 and 17 both exhibited high potency and selectivity toward ENPP1 (IC = 4.23 nM and 19.4 nM, respectively) with negligible ENPP2 inhibition (>10 μM) and weak ENPP3 inhibition (>3 μM). Both enhanced cGAMP-induced expression of STING pathway genes (IFNB1, CXCL10, IL6) in a concentration-dependent manner without cytotoxicity, producing stronger and more sustained activation than MV-658. This effect, dependent on the cGAMP-STING axis, was attributed to inhibition of ENPP1-mediated cGAMP hydrolysis. Additionally, compounds 15 and 17 showed no inhibition of the hERG channel (IC > 30 μM), indicating a favorable cardiac safety profile. In the CT-26 colorectal cancer model, compounds 15 and 17, administered at 40 mg/kg in combination with an anti-PD-1 antibody, achieved superior tumor growth inhibition (TGI: 73% and 67%, respectively), significantly prolonged survival, and were well tolerated with no observable body weight loss. These results establish 15 and 17 as promising ENPP1 inhibitors with favorable safety profiles, supporting their potential in combination cancer immunotherapy. - Source: PubMed
Publication date: 2026/08/25
He ZhiyueZhang YingyingZhan ShipingCao TianBai WanruZhou BozhiYu JieZeng HuiyingZhou JingyiTian FuyunChen XiaoyanZhang SulinZheng MingyueWu Xiaowei - The basophil activation test (BAT) is a modern in vitro functional assay used for the diagnosis of immunoglobulin E-mediated allergic reactions. The method is based on flow cytometric assessment of activation marker expression on peripheral blood basophils after stimulation with specific allergens. BAT has gained increasing clinical relevance in allergology, particularly in patients with anaphylaxis risk, polysensitization, drug hypersensitivity, and inconclusive skin or serological test results. This narrative review summarizes current evidence on the diagnostic performance and clinical applications of BAT in food allergy, drug hypersensitivity, Hymenoptera venom allergy, latex sensitization, and allergen immunotherapy monitoring. The review discusses the immunological mechanisms of basophil activation, the role of CD63 and CD203c, methodological aspects of the assay, sensitivity and specificity data, and advantages and limitations compared with conventional diagnostic approaches. Particular attention is given to protocol standardization, interpretation criteria, and the problem of non-responder patients. Current evidence indicates that BAT demonstrates high specificity and provides functional assessment of clinically relevant allergic reactions. In addition, this review proposes practical clinical frameworks for integrating BAT into allergy diagnostic pathways and for managing inconclusive or non-responder BAT results. Further standardization, multiplex formats, and automated analytical approaches may expand its role in personalized allergy diagnostics. - Source: PubMed
Publication date: 2026/07/09
Izmailovich MarinaKabyldina AizhanSeilkhan ZamiraZhussip AruzhanKozhanova RaushanNurpeissov TairUteubaeva GulzadaKazimirova OlgaLavrinenko AlyonaBrizitskaya LyubovSuleimanova ElinaShaikhina Zarina - Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with poor prognosis and limited curative treatment options. While chimeric antigen receptor (CAR) T cells have shown some promise in solid tumors, ACC remains largely unexplored in this context. Here, we used patient-derived xenograft (PDX) models of ACC to identify immunotherapeutic targets and develop novel CAR T-cell strategies. - Source: PubMed
Publication date: 2026/07/01
Okada ReonaMendoza ArnulfoNousome DarrylMathur SamarthRodriguez ConstanzaMaiarana JamesOh JangsukPendo KatiePhadke IraQin HaiyingSingh Sitanshu SKaplan RosieDel Rivero JaydiraWedekind Mary FEdmondson Elijah FMiettinen MarkkuWilson Kelli MLin ShinjenGomba Glenn YHolland David ODas SudiptoRudloff UdoAndresson ThorkellChih-Chien Cheng KenZhang XiyuanReilly Karlyne MWidemann BrigitteNguyen Rosa - There is a common basis of the diabetic nephropathy (DN) and diabetic retinopathy (DR), but the common genes of DN and DR were unclear. - Source: PubMed
Publication date: 2026/04/28
He JuanZhang DandanWang Yan - Nonsteroidal anti-inflammatory drugs (NSAID) are the second most frequent cause of drug-induced hypersensitivity after β-lactam antibiotics. Diagnosing cross-intolerance reactions to NSAIDs remains challenging because conventional allergy tests are not useful and drug provocation tests (DPT), the current criterion standard, are resource-intensive and carry risk of severe reactions. Basophil activation testing (BAT) has emerged as a potential ex vivo diagnostic alternative. This study aimed to evaluate the diagnostic utility of the BAT for cross-intolerance reactions to NSAIDs among Vietnamese patients, including the identification of optimal drug type, concentration, and cutoff values. This validation study used a case-control design that involved 38 patients previously diagnosed with cross-intolerance to NSAIDs and 34 healthy controls. The diagnosis of NSAID cross-intolerance was established according to the international consensus guidelines, based on a detailed clinical history and, when indicated, a DPT. Both groups underwent BAT by using two NSAIDs at two concentrations each: acetylsalicylic acid (ASA) at 1.25 mg/mL and 0.5 mg/mL, and ketorolac at 1.25 mg/mL and 0.5 mg/mL. Flow cytometric analysis was performed to assess basophil activation based on CD63 and CD203c expression. ASA 1.25 mg/mL showed the best BAT diagnostic performance for cross-intolerance, achieving 55.3% sensitivity and 91.2% specificity by using cutoffs of ≥4% activated basophils and stimulation index (SI) ≥ 1.5. BAT demonstrates moderate sensitivity but high specificity for NSAID cross-intolerance, particularly when ASA is used as the stimulant. These findings support BAT as a complementary confirmatory tool in selected patients at high risk, although negative results do not exclude hypersensitivity and DPT remains necessary when diagnostic confirmation is required. Further validation in clinically relevant populations is needed before routine clinical implementation. - Source: PubMed
Nguyen Anh QuynhNguyen Ha Thi NgocHo Nhan ThiVu Mai ThiPham Yen Thi HaiMai Hien ThiNguyen Han Hoang KimHoang Oanh ThiNguyen Nguyet Thi MinhChu Hieu Chivan Nunen SherylCraig Timothy JohnNguyen Tu DacNguyen Dinh Van